Grappling with metastatic risk: Bringing molecular imaging of met expression toward clinical use

Journal of Cellular Biochemistry

Volumn , Issue SUPPL. 39, 2002, Pages 184-193

  Hay, Rick ^a   Cao, Brian ^a   Tsarfaty, Ilan ^a   Tsarfaty, Galia ^a   Resau, James ^a   Vande Woude, George ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Confocal laser scanning microscopy (CLSM); Immunohistochemistry; Immunotherapy; Magnetic resonance imaging (MRI); Nuclear imaging; Receptor tyrosine kinase; Ultrasound

Indexed keywords

PROTEIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CANCER INVASION; CANCER RISK; CANCER THERAPY; HUMAN; IMAGING; METASTASIS; MOLECULAR IMAGING; ONCOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SOLID TUMOR; ANIMAL; DIAGNOSTIC IMAGING; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR MARKERS, BIOLOGICAL;

EID: 0036980850     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10441     Document Type: Article

References (33)

1. American Cancer Society. 2002. Cancer Facts and Figures 2002. New York.
2. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang L-M, Vande Woude GF. 2001. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 98:7443-7448.
3. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. 1984. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29-33.
4. Dean M, Park M, Le Beau MM, Robins TS, Diaz MO, Rowley JD, Blair DG, Vande Woude GF. 1985. The human met oncogene is related to the tyrosine kinase oncogenes. Nature 318:385-388.
5. Edakuni G, Sasatomi E, Satoh T, Tokanuga O, Miyazaki K. 2001. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 51:172-178.
6. Firon M, Shaharabany M, Altstock RT, Horev J, Abramovic A, Reseau JH, Vande Woude GF, Tsarfaty I. 2000. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene 19:2386-2397.
7. Ghoussoub RAD, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. 1998. Expression of c-Met is a strong independent prognostic factor in breast carcinoma. Cancer 82:1513-1520.
8. Haddad R, Lipson KE, Webb CP. 2001. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res 21:4243-4252.
9. Hay RV, Cao B, Skinner RS, Wang L-M, Su YL, Resau JH, Vande Woude GF, Gross MD. 2002a. Radioimmunoscintigraphy of tumors autocrine for human Met and hepatocyte growth factor/scatter factor. Mol Imaging 1:56-62.
10. Hay R, Cao B, Skinner RS, Wang L-M, Su Y, Resau J, Knudsen B, Vande Woude G, Gross M. 2002b. Radio-immunoscintigraphy of human Met-expressing tumor xenografts with Met3, an anti-Met monoclonal antibody. Cancer Biother Radiopharm 17:482 (Abstract).
11. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A. 2001. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98:15044-15049.
12. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. 1995. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386-396.
13. Iyer A, Kmiecik TE, Park M, Daar I, Blair D, Dunn KJ, Sutrave P, Ihle JN, Bodescot M, Vande Woude GF. 1990. Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ 1:87-95.
14. Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph A, Lamszus K, Park M, Goldberg ID, Rosen EM. 1997. Expression of scatter factor and c-Met receptor in benign and malignant breast tissue. Cancer 79:749-760.
15. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. 2002. High expression of the Met receptor in prostate cancer metastasis to bone. Urology (in press).
16. Koo H-M, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF. 2002. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci USA 99:3052-3057.
17. Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, Teh BS, Haab BB. 2003. Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers. Proteomics (in press).
18. Niemann C, Brinkmann V, Spitzer E, Hartmann G, Sachs M, Naundorf H, Birchmeier W. 1998. Reconstitution of mammary gland development in vitro: Requirement of c-Met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol 143:533-545.
19. Parker JA. 2001. Cardiac nuclear medicine in monitoring patients with coronary heart disease. Sem Nucl Med XXXI:223-237.
20. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LWK. 1995. C-Met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154:293-298.
21. Program and Abstracts, Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates. 2002. Cancer Biother Radiopharm 17:465-494.
22. Qian C-N, Guo X, Cao B, Kort EJ, Lee C-C, Chen J, Wang L-M, Mai W-Y, Min H-Q, Hong M-H, Vande Woude GF, Resau JH, Teh BT. 2002. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62:589-596.
23. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. 2001. Tissue microarray: A new technology for amplification of tissue resources. Cancer J 1:24-31.
24. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73.
25. Shaharabany M, Abramovitch R, Kushnir T, Tsarfaty G, Ravid-Megido M, Horev J, Ron R, Itzchak Y, Tsarfaty I. 2001. In vivo molecular imaging of Met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res 61:4873-4878.
26. Stuart KA, Riordan SM, Lidder S, Crostella L, Williams R, Skouteris GG. 2000. Hepatocyte growth factor/scatter factor-induced intracellular signalling. Int J Exp Pathol 81:17-30.
27. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT. 2001. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci USA 98:9754-9759.
28. Tsarfaty I, Alvord WG, Resau JH, Altstock RT, Lidereau R, Bieche I, Bertrand F, Horev J, Klabansky RL, Keydar I, Vande Woude GF. 1999. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal Quant Cytol Histol 21:397-408.
29. Tuck A, Park M, Sterns EE, Boag A, Elliott B. 1996. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148:225-232.
30. van der Voort R, Taher TEI, Derksen PWB, Spaargaren M, van der Neut R, Pals ST. 2000. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 79:39-90.
31. Watanabe M, Fukutome K, Kato H, Murata M, Kawamura J, Shiraishi T, Yatani R. 1999. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 141:173-178.
32. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF. 2000. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60: 342-349.
33. Yamashita JI, Ogawa M, Yamashita SI, Nomura K, Kuramoto M, Saishoji T, Shin S. 1994. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54:1630-1633.